Benchmarking nanopore sequencing and rapid genomics feasibility: validation at a quaternary hospital in New Zealand.
Denis M Nyaga, Peter Tsai, Clare Gebbie...
https://pubmed.ncbi.nlm.nih.gov/39516456/Actively Recruiting
Led by Liggins Institute · Updated on 2025-05-07
500
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are exploring how rapid whole-genome sequencing of parents and their newborn or young child can help identify genetic diseases in critically ill infants. The study focuses on patients in neonatal and pediatric intensive care units, aiming to improve diagnosis and precision medicine by understanding the genetic causes of severe illness. This research also seeks to understand the impact of genomic testing within New Zealands healthcare system and expand knowledge of genetic variants that affect early life disease. The study involves rapid whole genome sequencing, including advanced long-read RNA sequencing, to analyze the function of genetic variants. This genomic testing is used on acutely ill newborns and children up to 2 years old suspected of having genetic conditions. Researchers will examine the clinical usefulness of analyzing non-coding genetic variants and assess the medical and economic effects of applying rapid genomic information in real-world clinical care. Participants will be admitted patients in intensive care units, with genomic samples collected from the child and their parents. Researchers will monitor genetic data and its clinical application, including the impact on families and healthcare outcomes. The study will measure how genomic testing influences diagnosis and treatment decisions in early life severe illness, with results expected by June 2025. The total participation duration depends on hospital stay and sample collection timing.
CONDITIONS
Newborn Genomics Programme
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Liggins Institute
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week
Participants undergo rapid whole genome sequencing to investigate suspected genetic conditions.
1 visit (in-person)
Duration - Up to 3 years
Participants are observed to assess the clinical and economic effects of rapid whole genome sequencing-informed precision medicine in a real-world setting.
Follow-up visits as needed
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Denis M Nyaga, Peter Tsai, Clare Gebbie...
https://pubmed.ncbi.nlm.nih.gov/39516456/Liggins Institute
Lead Sponsor